Regeneron
4Q Revenues: $1.9 billion (+22%)
4Q Earnings: $820 million (+371%)
FY Revenues: $6.7 billion (+14%)
FY Earnings: $ 2.4 billion (+104%)
Comments: EYLEA Injection sales in the U.S. increased 11% to $1.1 billion. EYLEA sales outside the U.S., which are recorded by the Company’s collaborator Bayer, increased 14% to $724 million in the quarter. Libtayo Injection sales in the U.S. were $15 million in the first three months of launch. Dupixent Injection global net sales, which are recorded by the Company’s collaborator Sanofi, were $319 million in the quarter. The Company’s effective tax rate for both the quarter and full year 2018 was significantly impacted by the U.S. Tax Reform Act, which reduced the U.S. federal corporate income tax rate from 35% to 21% effective January 1, 2018.